Retrospective Study
Copyright ©The Author(s) 2016.
World J Transplant. Dec 24, 2016; 6(4): 703-711
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.703
Table 1 Relationship between various parameters at the time of liver transplantation and the incidence of hepatic steatosis on 10-year post-liver transplantation biopsy
All subjects n = 72No HS n = 48HS n = 24P1
Age (yr)35 ± 1932 ± 2142 ± 120.04
Gender (female)52%60%71%NS
Disease
Acute hepatic failure24%27%17%NS
Primary biliary cirrhosis25%25%25%NS
HBV-related cirrhosis8%6%12%NS
Autoimmune cirrhosis7%6%8%NS
Biliary atresia5%8%0%NS
HCV-related cirrhosis12%6%25%NS
Metabolic disease (Wilson disease)1%2%0%NS
Alcohol related cirrhosis1%2%0%NS
Primary sclerosing cholangitis4%4%4%NS
Cryptogenic cirrhosis2%4%0%NS
Hepatocellular carcinoma8%8%8%NS
ABO compatible97%96%100%NS
Donor age (years)27 ± 1127 ± 1227 ± 10NS
Donor gender (female)41%42%39%NS
Urgency25%27%21%NS
Cold ischemic time (min)410 ± 212406 ± 215429 ± 214NS
Reperfusion biopsy2
Steatosis (≥ 10%)18%15%22%NS
% of steatosis24 ± 1531 ± 1616 ± 8NS
Reperfusion lesions
Mild26%31%17%NS
Moderate to severe60%50%79%NS
Table 2 Relationship between various parameters at 10-year post-liver transplantation and the incidence of hepatic steatosis on 10-year post-liver transplantation biopsy
All subjects n = 72No HS n = 48HS n = 24P1
Age at the time of survey49 ± 1547 ± 1553 ± 12NS
≥ 60 yr aged patients28%27%29%NS
Histological lesions
Steatosis33%-100%
Macrovacuolar28%-82%
Microvacuolar1%-4%
Combined Mac-Mic4%-14%
Initial and 10-yr maintained steatosis8% (5 pat.)0%22%0.002
Fibrosis (F1-F4)53%44%71%0.03
F1-F240%35%50%NS
F3-F413%8%21%NS
Combined fibrosis-steatosis24%0%71%< 0.0001
HCV(+) Fibrosis44%31%71%< 0.001
Bile duct lesions36%42%25%NS
Minimal change23%27%17%NS
Other potential steatosis factors
BMI (kg/m2)22.4 ± 3.822.3 ± 3.922.6 ± 3.4NS
Underweight (BMI ≤ 18.5)13%17%4%
Normal weight (BMI = 18.5-24.9)69%65%79%NS
Overweight (BMI = 25-29.9)14%14%13%
Obesity (BMI ≥ 30)4%4%4%
HCV infection (de novo or recurrence)57%46%79%0.007
Arterial hypertension53%52%54%NS
Glycemia (mmol/L)5.4 ± 2.05.1 ± 0.96.2 ± 3.2NS
Diabeties mellitus10%8%13%NS
Maintenance immunosuppresssion
Cyclosporine A96%96%96%NS
Dosage (mg)129.8 ± 58.1135.0 ± 61.5119.5 ± 50.4NS
Prednisolone93%96%88%NS
Dosage (mg)6.8 ± 3.16.9 ± 3.26.7 ± 2.9NS
Azathioprine43%40%50%NS
Dosage (mg)48.4 ± 15.751.3 ± 15.543.8 ± 15.5NS
Table 3 Social life factors and hepatic steatosis at 10-year biopsy
All subjects n = 72No HS n = 48HS n = 24P1
Work
Employed33%39%23%NS
Homemaker13%17%4%NS
Student full/part-time3%4%0%NS
Unemployed20%19%23%NS
Retired30%21%50%0.03
No. of years worked17.9 ± 12.716.4 ± 12.620.9 ± 12.5NS
Alcohol and smoking
Alcohol consumption21%17%30%NS
No. of drinks2/d in drinkers1.1 ± 0.31.0 ± 0.01.2 ± 0.4NS
Tobacco smokers17%15%21%NS
Cigarettes/d in smokers1.9 ± 0.72.1 ± 0.71.6 ± 0.9NS
Table 4 Univariate analysis of subjective variables associated with hepatic steatosis at 10-year biopsy
QOL criteriaUnivariate P
Physical distress
Muscle weakness0.04
Abdominal pains or discomfort< 0.0001
Abdominal swelling or bloating0.04
Joint aches or pains< 0.001
Headaches0.03
Poor or blurred vision0.03
Change in facial appearance< 0.001
Fluid retention or swelling of ankles0.02
Psychological distress
Sleeplessness or insomnia0.03
Nervousness, anxiety0.009
Feeling depressed, sad or blue< 0.01
Low satisfaction with life as a whole0.02
Personal function
Health currently limits the kind of vigorous activities such as running, heavy lifting or sport< 0.001
Social and role function
Decreased interest in sex0.003
Problem with sex life0.04
General health perception
Bodily pain during the last month< 0.01
Table 5 Multivariate analysis of independent factors of hepatic steatosis at 10-year biopsy
FactorsMultivariate P
Objective factors
Retirement0.04
Hepatitis C virus infection (de novo or recurrence)< 0.01
Subjective factors
Abdominal pains or discomfort< 0.01
Joint aches or pains0.04